Elevance Health, Inc. (ELV) continues to trend as one of the top health insurance stocks to invest in. The firm has demonstrated a dominant presence in the market, heatedly anticipated by investors for their robust performance.
D1 Capital's Daniel Sundheim further affirms this, recognising ELV as among the best stocks to buy. Notably, investing $1000 twenty years ago in ELV would have yielded substantial returns. Despite various setbacks such as increasing expenses that resulted in the curbing of online Medicare sign-ups, and potential caution indicated by insider US$6.9m stock sale, the company surges ahead with impressive Q1 2025 results. ELV has seen a
strong EPS growth, successfully topping sales estimates and returning solid Q4 results. However, controversy is not far behind with allegations of 'Ghost Network' against the company's associates, Carelon Behavioral Health, by the Justice Department, suggesting possible kickbacks. Despite a slide in Q4 by ELV, Wall Street Expects Earnings Growth. ELV still exhibits diversity in its stock character, with a rise of 5.4% indicating further growth potential. Amid all the turbulence, ELV is considered a hidden gem in healthcare, optimistically regarded for continuing its upsurge assisted by a strong MA business and positive Q1 earnings.
Barclays has also recently upgraded ELV to a 'Buy'.
Elevance Health ELV News Analytics from Thu, 17 Oct 2024 07:00:00 GMT to Fri, 02 May 2025 15:05:00 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
